SG11201810847RA - Non-invasive diagnostic imaging agent for heart disease - Google Patents
Non-invasive diagnostic imaging agent for heart diseaseInfo
- Publication number
- SG11201810847RA SG11201810847RA SG11201810847RA SG11201810847RA SG11201810847RA SG 11201810847R A SG11201810847R A SG 11201810847RA SG 11201810847R A SG11201810847R A SG 11201810847RA SG 11201810847R A SG11201810847R A SG 11201810847RA SG 11201810847R A SG11201810847R A SG 11201810847RA
- Authority
- SG
- Singapore
- Prior art keywords
- heart disease
- imaging agent
- diagnostic imaging
- invasive diagnostic
- invasive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention addresses the problem of providing a technique for detecting a lesion of a heart disease in a non-invasive manner. The present invention 5 provides a non-invasive diagnostic imaging agent for a heart disease, which contains a radioactively labeled compound capable of binding to an aldosterone synthase or a salt thereof as an active ingredient. - 1 - Figure 1 Figure 2 - 2 - Figure 3 Figure 4 - 3 - Figure 5 Figure 6 - 4 - Figure 7 - 5 - Figure 8 Figure 9 - 6 - Figure 10 Figure 11 - 7 - Figure 12 Figure 13 - 8 - Figure 14
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016115806 | 2016-06-10 | ||
| PCT/JP2017/021442 WO2017213247A1 (en) | 2016-06-10 | 2017-06-09 | Non-invasive diagnostic imaging agent for heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810847RA true SG11201810847RA (en) | 2019-01-30 |
Family
ID=60577959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810847RA SG11201810847RA (en) | 2016-06-10 | 2017-06-09 | Non-invasive diagnostic imaging agent for heart disease |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190255199A1 (en) |
| EP (1) | EP3470091A4 (en) |
| JP (1) | JPWO2017213247A1 (en) |
| KR (1) | KR20190016971A (en) |
| CN (1) | CN109310787A (en) |
| AU (1) | AU2017278446A1 (en) |
| CA (1) | CA3026617A1 (en) |
| SG (1) | SG11201810847RA (en) |
| WO (1) | WO2017213247A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7209970B2 (en) * | 2017-12-28 | 2023-01-23 | 日本メジフィジックス株式会社 | 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimidazole derivative compound and medicine containing the same |
| JP2021130610A (en) * | 2018-05-08 | 2021-09-09 | 日本メジフィジックス株式会社 | Non-invasive diagnostic imaging agent for heart disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602008003015D1 (en) * | 2007-03-29 | 2010-11-25 | Novartis Ag | HETEROCYCLIC SPIRO COMPOUNDS |
| JP5196561B2 (en) * | 2007-11-07 | 2013-05-15 | 独立行政法人放射線医学総合研究所 | Nuclear medicine diagnostic medicine |
| DE102008022221A1 (en) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitors of human aldosterone synthase CYP11B2 |
| CN102666535B (en) * | 2009-11-30 | 2015-02-25 | 诺华股份有限公司 | Imidazole derivatives as aldosterone synthase inhibitors |
| EP2394668A1 (en) | 2010-06-01 | 2011-12-14 | Julius-Maximilians-Universität Würzburg | PET radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism |
| US9353081B2 (en) | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| JP6048958B2 (en) | 2012-12-27 | 2016-12-21 | 日本メジフィジックス株式会社 | Diagnostic agents for adrenal diseases |
| JP2015093831A (en) | 2013-11-08 | 2015-05-18 | 日本メジフィジックス株式会社 | Aldosterone synthase inhibitor |
| JP2015093833A (en) | 2013-11-08 | 2015-05-18 | 日本メジフィジックス株式会社 | Radioactive halogen labeled compounds or salts thereof, and pharmaceuticals containing the same |
| JP2015110563A (en) | 2013-11-08 | 2015-06-18 | 日本メジフィジックス株式会社 | Aldosterone synthase inhibitor |
| JP2015093832A (en) | 2013-11-08 | 2015-05-18 | 日本メジフィジックス株式会社 | Radioactive halogen labeled compounds or salts thereof, and pharmaceuticals containing the same |
| JP2015193545A (en) | 2014-03-31 | 2015-11-05 | 国立大学法人京都大学 | 2-(3-pyridinyl)-1h-benzimidazole derivative compound, and radioactive pharmaceuticals containing the same |
| JP6313098B2 (en) | 2014-04-04 | 2018-04-18 | イーデーエム株式会社 | Thermal printer |
| WO2015199205A1 (en) * | 2014-06-26 | 2015-12-30 | 日本メジフィジックス株式会社 | 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same |
-
2017
- 2017-06-09 CN CN201780035800.9A patent/CN109310787A/en active Pending
- 2017-06-09 CA CA3026617A patent/CA3026617A1/en not_active Abandoned
- 2017-06-09 WO PCT/JP2017/021442 patent/WO2017213247A1/en unknown
- 2017-06-09 SG SG11201810847RA patent/SG11201810847RA/en unknown
- 2017-06-09 AU AU2017278446A patent/AU2017278446A1/en not_active Abandoned
- 2017-06-09 JP JP2018521787A patent/JPWO2017213247A1/en active Pending
- 2017-06-09 KR KR1020187036667A patent/KR20190016971A/en unknown
- 2017-06-09 EP EP17810420.4A patent/EP3470091A4/en not_active Withdrawn
- 2017-06-09 US US16/308,014 patent/US20190255199A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190255199A1 (en) | 2019-08-22 |
| JPWO2017213247A1 (en) | 2019-04-04 |
| AU2017278446A1 (en) | 2018-12-20 |
| EP3470091A4 (en) | 2019-06-19 |
| KR20190016971A (en) | 2019-02-19 |
| CN109310787A (en) | 2019-02-05 |
| CA3026617A1 (en) | 2017-12-14 |
| WO2017213247A1 (en) | 2017-12-14 |
| EP3470091A1 (en) | 2019-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34057B1 (en) | Formulations and methods for the diagnosis and treatment of tumor | |
| WO2015134464A3 (en) | Targeted therapeutics | |
| MX2022002401A (en) | Radiopharmaceuticals, radioimaging agents, and uses thereof. | |
| MX2021003311A (en) | Probes for imaging huntingtin protein. | |
| WO2015092020A3 (en) | Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine | |
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| PH12015501744B1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
| WO2013158644A3 (en) | Targeted therapeutics | |
| MX2015005948A (en) | Polypeptides for blood brain barrier transport. | |
| JOP20200231A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
| CN107406464A8 (en) | Arginase inhibitor and its therapeutical uses | |
| WO2015066053A8 (en) | Targeted therapeutics | |
| MX2015012528A (en) | Macrocyclic salt-inducible kinase inhibitors. | |
| PH12020500354A1 (en) | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis | |
| EP3088898A4 (en) | Method for diagnosis of alzheimer's disease and frontotemporal lobar degeneration, diagnostic agent, therapeutic agent, and screening method for said agents | |
| EA201890221A1 (en) | HBED BISPHOSPHONATE, THEIR CONJUGATES WITH RADIOMETAL AND THEIR USE AS MEDICAL TREATMENT DIAGNOSTIC AGENTS | |
| IL257872A (en) | Crystalline form of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethanone for the treatment of parkinson's disease | |
| WO2017105565A3 (en) | Compositions for therapeutics, targeted pet imaging and methods of their use | |
| SG11201810847RA (en) | Non-invasive diagnostic imaging agent for heart disease | |
| WO2015062726A3 (en) | Hcbi sequences as an early marker for the future development of cancer and diseases of the cns and as a target for cancer treatment and prevention | |
| EP3741105A4 (en) | Ionizing radiation-free dental imaging by near-infrared fluorescence, and related systems | |
| MX2018000336A (en) | Peritoneal therapeutic fluid. | |
| BR112017026003A2 (en) | ? diagnostic imaging agent for early bone metastasis of cancer? | |
| EP3685144A4 (en) | Imaging biological tissue or other subjects |